Potential Catalysts in September:

- Completion of Kevetrin (Phase 1)
- Start of K-AML (Phase 2)
- Trial Design on B-ABSSSI (Phase 3)
- Enrollment Status of B-OM & Prurisol (Phase 2)
- 10-K / Nasdaq Uplist
- Corporate Update